Our guest today, Dr. Yoni Freedhoff, Associate Professor of Family Medicine at the University of Ottawa and Medical Director of The Bariatric medical Institute discusses an article on his blog that outlines how Lilly, manufacturer of Mounjaro, an injectable medication used for the treatment of Type 2 Diabetes and obesity is effectively charging more for the same drug if it is being used to treat obesity.

I also discuss how insurance companies should not be in the business of interfering with the medical management of patients especially when the standard of care is applied to their particular situation.

Also, many young adults using the OHIP+ coverage for medications lose this publicly funded pharmacare access when they reach age 25. So if being treated for chronic disease, they end up relapsing because they have insufficient fund and/or no private insurance to fill the gap. Ergo, they needlessly suffer.

Your calls and questions:

• The difference between Mounjaro and Ozempic
• How effective is Contrave for the treatment of Obesity
• A woman injured her knee while using the stairs while she was visiting the Amalfi Coast. Now has difficult walking. She would like to know what she should do.
• A 75 year old woman recounts how Ozempic has changed her life for the better.

Playlist for the show:

1st segment

Intro:  Your Mother Should Know – The Beatles

Outro: Don’t You Forget About Me – Simple Minds

2nd segment

Intro: Mother and Child Reunion – Paul Simon

Outro: She Talks to Angels – The Black Crowes (start at 1:15)

3rd segment

Intro: Give a Little Bit – Supertramp

Outro: Your Song – Elton John

4th segment

Intro:  Home – Phillip Phillips

Outro: Lullabye (Goodnight, My Angel) – Billy Joel